Halozyme Therapeutics, Inc. is a biotechnology company operating in the healthcare sector, focused on developing drug delivery technologies that improve the administration of biologic therapies.

Its core activities include:

• Development of drug delivery technologies for biologic therapies.
• Licensing of proprietary biotechnology platforms.
• Strategic partnerships with pharmaceutical and biotechnology companies.
• Research and development of innovative subcutaneous drug delivery solutions.

The company’s main innovation is the Enhanze platform, which is based on a recombinant human hyaluronidase enzyme designed to enhance the absorption and dispersion of injected drugs in subcutaneous tissue. This technology allows certain biologic therapies that traditionally require intravenous infusion to be administered more quickly through subcutaneous injection.

Company performance is influenced by the adoption of its drug delivery platform by pharmaceutical partners, regulatory approvals for partnered therapies, research and development progress, and broader trends in the biopharmaceutical industry.

Halozyme Therapeutics, Inc. shares trade on the Nasdaq under the ticker HALO.

History and Development

Halozyme was founded in 1998 in San Diego, California, with the objective of developing technologies that improve the delivery of injectable biologic medicines.

In its early years, the company focused on research and development of the Enhanze platform while establishing strategic collaborations with pharmaceutical partners.

The company completed its initial public offering (IPO) on the Nasdaq in 2004, raising capital to support further research, technology development, and partnership expansion.

Over time, Halozyme expanded the number of pharmaceutical companies using its platform, strengthening its licensing and royalty-based business model while broadening the applications of its drug delivery technology.